IL
London, England, GB
Isomorphic Labs
British AI drug discovery company founded in 2021, using machine learning and protein structure prediction to design molecules and advance candidates in oncology and immunology.
Isomorphic Labs is a British drug discovery company founded in 2021 that applies artificial intelligence to the modelling of biological phenomena, the design of novel molecules and the development of new medicines. It is led by chief executive Sir Demis Hassabis, the 2024 Nobel laureate in Chemistry. The firm treats biology as an information-processing system and pursues scientific discovery at digital speed, with an interdisciplinary team spanning drug discovery expertise and machine learning.
Its core asset is a unified AI drug design engine that operates across multiple therapeutic areas and drug modalities, allowing work that would traditionally be done experimentally to be conducted in silico. The technical repertoire behind it includes protein structure prediction, notably AlphaFold, as well as generative and predictive AI models, computational biology and molecular design. Alongside the platform, the company runs an internal pipeline of drug candidates in oncology and immunology.
Isomorphic Labs has entered into pharmaceutical partnerships with Eli Lilly, Novartis and Johnson & Johnson. The company is based in the United Kingdom and operates across the pharmaceutical, biotechnology and healthcare sectors.